Hemostemix's Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat P
Biotechnology, Pharmaceuticals, Health
2025-08-14 9:17 AM EDT | Hemostemix Inc.
Entero Therapeutics, Inc. Announces Reverse Stock Split
Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on A
Biotechnology, Pharmaceuticals
2025-08-14 9:15 AM EDT | Entero Therapeutics, Inc.
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders. Dear Fellow Shareholders, Earlier this year, I wrote to you about the challenges we faced with our
Biotechnology, Pharmaceuticals
2025-08-14 8:00 AM EDT | PharmaTher Holdings Ltd.
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone payments Following the transaction, Adaptimmune has repaid its debt and is restructuring to maximize
Biotechnology, Healthcare and Hospitals
2025-08-13 7:30 AM EDT | Adaptimmune Therapeutics PLC
Neural Announces Completion of the Acquisition of a 30.75% Interest in Hanf.com, a Profitable German CBD Retail Store Chain
Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-13 7:30 AM EDT | Neural Therapeutics Inc.
MustGrow annonce un placement sans intermédiaire sous le régime de la dispense pour financement de l'émetteur coté d'un montant maximal de 3 millions de dollars, une proposition de révision du prix des bons de souscription, et une offre d'actions aux porteurs de débentures aux fins du règlement de dettes
Saskatoon, Saskatchewan--(Newsfile Corp. - 12 août 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (la « Société » ou « MustGrow »), a le plaisir d'annoncer ce qui suit : i) un placement privé sans intermédiaire d'un maximum de 4 285 715 unités de la Société (chacune, une « unité ») au prix de 0,70 $ par unité pour un produit brut pouvant atteindre 3 000 000 $ (l
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-08-12 7:46 PM EDT | MustGrow Biologics Corp.
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's potential Management to host conferenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-12 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it contracted Empire Market Ventures to provide an investor market awareness program. Empire Market Ventures (EMV) is a premier consulting firm and full-service advertising and investor awareness agency based in New York City. Specializing in strategic communications, digital media, and market intelligence, EMV delivers tailored solutions that enhance the visibility
Biotechnology, Pharmaceuticals, Health
2025-08-12 10:01 AM EDT | Hemostemix Inc.
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING") to explore the clinical application of BioMark's innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader Nor
Technology, Biotechnology, Healthcare and Hospitals
2025-08-12 8:30 AM EDT | BioMark Diagnostics, Inc.
Izotropic Introduces New Corporate Website & Brand Identity
British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new corporate website
2025-08-12 8:00 AM EDT | Izotropic Corporation
Quantum BioPharma Announces Update to Previously Announced Private Placement
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-11 6:32 PM EDT | Quantum BioPharma Ltd.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees. The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company a
2025-08-11 6:05 PM EDT | Marvel Biosciences Corp.
PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it received the U.S. Food and Drug Administration (FDA) approval for the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain manag
Biotechnology, Pharmaceuticals
2025-08-11 9:49 AM EDT | PharmaTher Holdings Ltd.
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market
Biotechnology, Pharmaceuticals
2025-08-11 7:30 AM EDT | Entero Therapeutics, Inc.
BioHarvest Sciences Reports Second Quarter 2025 Financial Results
Rehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights All figures stated in this news release are in U.S. dollars unless stat
Biotechnology, Pharmaceuticals, Health
2025-08-11 7:30 AM EDT | BioHarvest Sciences Inc.
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. A live webcast o
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-08-11 7:27 AM EDT | Cardiol Therapeutics Inc.
Scryb Inc. Provides Early Warning Update on Holdings In Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - August 8, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb") is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer"). This press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids ("NI 62-104") and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues
Biotechnology, Healthcare and Hospitals, Health
2025-08-08 8:25 PM EDT | Scryb Inc.
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second quarter and 2025 year-to-date corporate highlights include: KIO-104 Initiated
Biotechnology, Pharmaceuticals
2025-08-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Scryb Announces Effective Date of Proposed Share Consolidation
Toronto, Ontario--(Newsfile Corp. - August 7, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) ("Scryb'' or the "Company"), is pleased to announce that further to its news release dated July 25, 2025, the Company will proceed with the consolidation of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) new Common Share for every ten (10) old Common Shares (the "Consolidation"), effective as of August 13, 2025. The Consolidation
Biotechnology, Healthcare and Hospitals, Health
2025-08-07 10:20 PM EDT | Scryb Inc.
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow
Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem. iSpecimen has retained WestPark Capital to advise on the initiative
2025-08-07 4:05 PM EDT | iSpecimen Inc.